![An Bang Lu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
An Bang Lu
Chief Executive Officer at VISEN Pharmaceuticals
An Bang Lu active positions
Companies | Position | Start | End |
---|---|---|---|
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Director/Board Member | 06/11/2018 | - |
Chief Executive Officer | 06/11/2018 | - | |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
![]() VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Director/Board Member | - | - |
Chief Executive Officer | - | - |
Career history of An Bang Lu
Former positions of An Bang Lu
Companies | Position | Start | End |
---|---|---|---|
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
![]() VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Director/Board Member | - | 31/05/2021 |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | President | 31/12/2009 | 31/12/2013 |
Training of An Bang Lu
Taipei Medical University | Undergraduate Degree |
Statistics
International
Cayman Islands | 2 |
Japan | 2 |
China | 2 |
Operational
Director/Board Member | 3 |
Chief Executive Officer | 2 |
President | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
Private companies | 2 |
---|---|
VISEN Pharmaceuticals
![]() VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Health Technology |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
![]() VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Health Technology |
- Stock Market
- Insiders
- An Bang Lu
- Experience